Sun Pharmaceutical Industries has launched four authorized generics belonging Daiichi Sankyo in US, for all strengths of olmesartan medoxomil tablets – therapeutic equivalent Benicar tablets, olmesartan medoxomil-hydrochlorothiazide tablets – therapeutic equivalent Benicar HCT tablets,  amlodipine besylate-olmesartan medoxomil tablets – therapeutic equivalent  Azor  tablets; and amlodipine besylate-hydrochlorothiazide-olmesartan medoxomil tablets – therapeutic equivalent Tribenzor tablets.

The launch is pursuant to a distribution and supply agreement between Sun Pharma’s wholly owned subsidiary and Daiichi Sankyo Inc., which grants the Sun Pharma subsidiary, exclusive rights to distribute these tablets in the US for a pre-determined period. Benicar, Benicar HCT, Azor and Tribenzor recorded US sales of approximately US$ 2.5 billion for the 12 months ending August 31, 2016, as per IMS Health.